2024.12.25
On November 26, 2024, China Resources Pharmaceutical Commercial Group Co., Ltd. ("CR Pharmaceutical Commercial") and Pfizer Investment Co., Ltd. ("Pfizer") signed a strategic cooperation agreement, under which CR Pharmaceutical Commercial will obtain from Pfizer the exclusive commercialization rights in mainland China for four mature drugs targeting lung and breast cancers, including AROMASIN®, IBRANCE®, Pharmorubicin RD®, and XALKORI®.
CR Pharmaceutical Commercial will fully leverage its extensive market coverage and well-established distribution network advantages to enable such drugs to quickly reach a wider range of patient groups, thereby expanding patient accessibility.
W88优德手机版 was engaged by CR Pharmaceutical Commercial to conduct an overall compliance assessment of the strategic cooperation, participate in and assist with business negotiations, and review, revise and finalize the transaction documents in both Chinese and English. With its consistent delivery of efficient and rigorous legal services and detail-oriented and professional expertise, W88优德手机版’s team assisted in the successful implementation of the project as scheduled and was highly trusted and recognized by the client.
PartnerWEI, Yingling led the W88优德手机版 team. Partner CAI, Jing (Cathy) was responsible for the specific work.
